COMMUNIQUÉS West-GlobeNewswire

Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence

27/03/2018 - 13:00

NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders [...]

Antares Pharma Provides XYOSTED™ Regulatory Update

27/03/2018 - 13:00

EWING, N.J., March 27, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS ) (the Company) today announced that the official minutes from the Type A meeting with the U.S. Food and Drug Administration (FDA or the [...]

Summit Therapeutics Announces Placement of £15.0 Million of Ordinary Shares

27/03/2018 - 13:00

OXFORD, United Kingdom, March 27, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. [...]

Prospectus relating to Active Biotech's rights issue published

27/03/2018 - 09:40

2018-03-27 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD [...]

Summit Therapeutics Announces a Proposed Placing to Raise up to £15 Million

27/03/2018 - 08:01

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE TO DO SO MIGHT [...]

Tecan publishes 2017 Annual Report and notice of its Annual General Meeting

27/03/2018 - 07:31

Männedorf, Switzerland, March 27, 2018 - The Tecan Group (SIX Swiss Exchange: TECN) today announced the publication of its 2017 Annual Report in the Investor Relations section of the company's website at www.tecan.com [...]

Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities

27/03/2018 - 07:01

Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term interests of Novartis [...]

Probiodrug AG to Publish its Full Year 2017 Results on 3 April 2018

27/03/2018 - 07:00

Probiodrug AG to Publish its Full Year 2017 Results on 3 April 2018 HALLE (SAALE), Germany, 27 March 2018 - Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel [...]

VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN

27/03/2018 - 06:57

Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa ® in Japan Potential of Veltassa ® further validated with expansion into Japanese market Deal expands cardio-renal network with Vifor Pharma's [...]

Aslan Pharmaceuticals Files for Proposed Initial Public Offering in the U.S.

27/03/2018 - 03:00

SINGAPORE, March 26, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the [...]

Hua Medicine Raises $117.4 Million in Series D & Series E Financing

27/03/2018 - 02:00

HONG KONG and SHANGHAI, China, March 26, 2018 (GLOBE NEWSWIRE) -- Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a [...]

BioStem Technologies, Inc. Announces Letter of Intent with CCM Pharma Solutions to Co-Develop Multiple Solid to Liquid Dose Drugs Through 505(b)(2) Accelerated FDA Approval Process

27/03/2018 - 01:22

Pompano Beach, FL, March 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation providing innovative technologies with a focus in [...]

R1 Appoints Alex Mandl as Lead Director

26/03/2018 - 23:00

Steve Shulman Resigns as Chairman of the Board Bert Zimmerli Appointed as Director CHICAGO, March 26, 2018 (GLOBE NEWSWIRE) -- R1 RCM Inc. (“R1” or the “Company”) (NASDAQ: RCM ), a leading provider of technology-enabled [...]

Matinas BioPharma Reports 2017 Financial Results

26/03/2018 - 22:45

BEDMINSTER, N.J., March 26, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications [...]

Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy

26/03/2018 - 22:30

GAITHERSBURG, Md., March 26, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced executive management changes that continue to align its organizational structure to its long-term strategy [...]

Intercept to Present at Upcoming Conference

26/03/2018 - 22:30

NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]

Quotient Limited Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction

26/03/2018 - 22:15

Verification & Validation (“V&V”) “head-to-head” data exceeds target concordance for blood grouping Overall concordance for antigen typing – 99.8%, demonstrating robustness of the MosaiQ platform Completion of [...]

Eyenovia Appoints Three Industry Veterans to Board of Directors

26/03/2018 - 22:05

NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN ), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to [...]

AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients

26/03/2018 - 22:05

46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerated 500mg cumulative peanut challenge at 14 days after a single dose of ANB020 compared to zero percent dosed with placebo Concomitant [...]